Key clinical point: Enzalutamide improves outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) in a prospective real-world study.

Major finding: The median time to treatment failure in chemotherapy and abiraterone-naïve patients was 12.9 months and those who were previously treated with chemotherapy and were abiraterone naïve was 8.4 months.

Study details: A prospective, observational PREMISE study of 1,732 patients with mCRPC who received enzalutamide.

Disclosures: This study was sponsored by Astellas Pharma Inc. The authors received honoraria, travel funds, grants, consulting/personal fees, and financial and nonfinancial support from various sources. Some authors reported being employed by an organization/foundation that receives funding from various private and public sector sources.

Source: Payne H et al. Int J Cancer. 2021 Oct 14. doi: 10.1002/ijc.33845.

Key clinical point: Enzalutamide improves outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) in a prospective real-world study.

Major finding: The median time to treatment failure in chemotherapy and abiraterone-naïve patients was 12.9 months and those who were previously treated with chemotherapy and were abiraterone naïve was 8.4 months.

Study details: A prospective, observational PREMISE study of 1,732 patients with mCRPC who received enzalutamide.

Disclosures: This study was sponsored by Astellas Pharma Inc. The authors received honoraria, travel funds, grants, consulting/personal fees, and financial and nonfinancial support from various sources. Some authors reported being employed by an organization/foundation that receives funding from various private and public sector sources.

Source: Payne H et al. Int J Cancer. 2021 Oct 14. doi: 10.1002/ijc.33845.

Key clinical point: Enzalutamide improves outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) in a prospective real-world study.

Major finding: The median time to treatment failure in chemotherapy and abiraterone-naïve patients was 12.9 months and those who were previously treated with chemotherapy and were abiraterone naïve was 8.4 months.

Study details: A prospective, observational PREMISE study of 1,732 patients with mCRPC who received enzalutamide.

Disclosures: This study was sponsored by Astellas Pharma Inc. The authors received honoraria, travel funds, grants, consulting/personal fees, and financial and nonfinancial support from various sources. Some authors reported being employed by an organization/foundation that receives funding from various private and public sector sources.

Source: Payne H et al. Int J Cancer. 2021 Oct 14. doi: 10.1002/ijc.33845.

Key clinical point: Salvage low-dose-rate (LDR) prostate brachytherapy shows good survival in patients with low-/intermediate-risk prostate cancer who had local failure after external beam radiotherapy (EBRT).

Major finding: The median follow-up was 6.7 years. At 10 years, the overall survival rate was 70%, disease-free survival rate was 33%, and disease-specific survival rate was 70%. Local-, distant-, and biochemical failure rates were 5%, 19%, and 46%, respectively.

Study details: A phase 2 study of 100 patients with low-/intermediate-risk prostate cancer who received salvage LDR prostate brachytherapy for local failure after EBRT.

Disclosures: This work was supported by National Cancer Institute.

Source: Crook J et al. Int J Radiat Oncol Biol Phys. 2021 Nov 2. doi: 10.1016/j.ijrobp.2021.10.138.

Key clinical point: Salvage low-dose-rate (LDR) prostate brachytherapy shows good survival in patients with low-/intermediate-risk prostate cancer who had local failure after external beam radiotherapy (EBRT).

Major finding: The median follow-up was 6.7 years. At 10 years, the overall survival rate was 70%, disease-free survival rate was 33%, and disease-specific survival rate was 70%. Local-, distant-, and biochemical failure rates were 5%, 19%, and 46%, respectively.

Study details: A phase 2 study of 100 patients with low-/intermediate-risk prostate cancer who received salvage LDR prostate brachytherapy for local failure after EBRT.

Disclosures: This work was supported by National Cancer Institute.

Source: Crook J et al. Int J Radiat Oncol Biol Phys. 2021 Nov 2. doi: 10.1016/j.ijrobp.2021.10.138.

Key clinical point: Salvage low-dose-rate (LDR) prostate brachytherapy shows good survival in patients with low-/intermediate-risk prostate cancer who had local failure after external beam radiotherapy (EBRT).

Major finding: The median follow-up was 6.7 years. At 10 years, the overall survival rate was 70%, disease-free survival rate was 33%, and disease-specific survival rate was 70%. Local-, distant-, and biochemical failure rates were 5%, 19%, and 46%, respectively.

Study details: A phase 2 study of 100 patients with low-/intermediate-risk prostate cancer who received salvage LDR prostate brachytherapy for local failure after EBRT.

Disclosures: This work was supported by National Cancer Institute.

Source: Crook J et al. Int J Radiat Oncol Biol Phys. 2021 Nov 2. doi: 10.1016/j.ijrobp.2021.10.138.

Key clinical point: After the first screening round, carriers of MSH2 and MSH6 pathogenic variants had a higher incidence of prostate cancer vs age-matched noncarrier controls.

Major finding: Men with MSH2 (P = .011) and MSH6 (P = .034) carriers showed a higher incidence of prostate cancer (prostate-specific antigen [PSA] threshold of 3 ng/mL or higher) vs noncarrier individuals. The overall positive predictive value of biopsy using a PSA threshold of 3 ng/mL was 51.4%.

Study details: An international, prospective IMPACT study of 644 men without a previous prostate cancer diagnosis and with a known germline pathogenic variant in the MLH1, MSH2, or MSH6 gene and 184 age-matched male controls without a familial pathogenic variant in these genes.

Disclosures: This study was supported by Cancer Research UK, the Ronald and Rita McAulay Foundation, and others. The authors received honoraria and/or speaker fees and reported owning patents licensed to and stocks in Arctic Partners.

Source: Bancroft EK et al. Lancet Oncol. 2021 Oct 19. doi: 10.1016/S1470-2045(21)00522-2.

Key clinical point: After the first screening round, carriers of MSH2 and MSH6 pathogenic variants had a higher incidence of prostate cancer vs age-matched noncarrier controls.

Major finding: Men with MSH2 (P = .011) and MSH6 (P = .034) carriers showed a higher incidence of prostate cancer (prostate-specific antigen [PSA] threshold of 3 ng/mL or higher) vs noncarrier individuals. The overall positive predictive value of biopsy using a PSA threshold of 3 ng/mL was 51.4%.

Study details: An international, prospective IMPACT study of 644 men without a previous prostate cancer diagnosis and with a known germline pathogenic variant in the MLH1, MSH2, or MSH6 gene and 184 age-matched male controls without a familial pathogenic variant in these genes.

Disclosures: This study was supported by Cancer Research UK, the Ronald and Rita McAulay Foundation, and others. The authors received honoraria and/or speaker fees and reported owning patents licensed to and stocks in Arctic Partners.

Source: Bancroft EK et al. Lancet Oncol. 2021 Oct 19. doi: 10.1016/S1470-2045(21)00522-2.

Key clinical point: After the first screening round, carriers of MSH2 and MSH6 pathogenic variants had a higher incidence of prostate cancer vs age-matched noncarrier controls.

Major finding: Men with MSH2 (P = .011) and MSH6 (P = .034) carriers showed a higher incidence of prostate cancer (prostate-specific antigen [PSA] threshold of 3 ng/mL or higher) vs noncarrier individuals. The overall positive predictive value of biopsy using a PSA threshold of 3 ng/mL was 51.4%.

Study details: An international, prospective IMPACT study of 644 men without a previous prostate cancer diagnosis and with a known germline pathogenic variant in the MLH1, MSH2, or MSH6 gene and 184 age-matched male controls without a familial pathogenic variant in these genes.

Disclosures: This study was supported by Cancer Research UK, the Ronald and Rita McAulay Foundation, and others. The authors received honoraria and/or speaker fees and reported owning patents licensed to and stocks in Arctic Partners.

Source: Bancroft EK et al. Lancet Oncol. 2021 Oct 19. doi: 10.1016/S1470-2045(21)00522-2.

Key clinical point: The risk for grade 3-4 (G3-4) neutropenia and febrile neutropenia (FN) is higher with FOLFOXIRI/bevacizumab vs doublets/bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC), with the risk being higher in older females, who may benefit with prophylactic use of granulocyte colony-stimulating factor.

Major finding: The incidence of G3-4 neutropenia (51% vs 21%; P < .001), FN (8% vs 4%; P = .02), and high-risk FN (3% vs 1%; P = .015) was significantly higher with FOLFOXIRI/bevacizumab vs doublet/bevacizumab, mostly during the first cycles. The risk for G3-4 neutropenia was significantly higher among older patients (P = .01) and females (P < .001).

Study details: This pooled analysis included 1,155 patients with untreated mCRC from TRIBE1 and TRIBE 2 phase 3 trials, of which 568 patients received FOLFOXIRI/bevacizumab and 587 received doublet/bevacizumab (FOLFIRI/bevacizumab; n=254 or FOLFOX/bevacizumab; n=335).

Disclosures: This study was supported by GONO and ARCO Foundations. Some of the authors declared receiving honoraria, travel grant, research funding, speakers’ bureau, and/or consulting or advisory role for various sources.

Source: Rossini D et al. ESMO Open. 2021 Oct 21. doi: 10.1016/j.esmoop.2021.100293.

Key clinical point: The risk for grade 3-4 (G3-4) neutropenia and febrile neutropenia (FN) is higher with FOLFOXIRI/bevacizumab vs doublets/bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC), with the risk being higher in older females, who may benefit with prophylactic use of granulocyte colony-stimulating factor.

Major finding: The incidence of G3-4 neutropenia (51% vs 21%; P < .001), FN (8% vs 4%; P = .02), and high-risk FN (3% vs 1%; P = .015) was significantly higher with FOLFOXIRI/bevacizumab vs doublet/bevacizumab, mostly during the first cycles. The risk for G3-4 neutropenia was significantly higher among older patients (P = .01) and females (P < .001).

Study details: This pooled analysis included 1,155 patients with untreated mCRC from TRIBE1 and TRIBE 2 phase 3 trials, of which 568 patients received FOLFOXIRI/bevacizumab and 587 received doublet/bevacizumab (FOLFIRI/bevacizumab; n=254 or FOLFOX/bevacizumab; n=335).

Disclosures: This study was supported by GONO and ARCO Foundations. Some of the authors declared receiving honoraria, travel grant, research funding, speakers’ bureau, and/or consulting or advisory role for various sources.

Source: Rossini D et al. ESMO Open. 2021 Oct 21. doi: 10.1016/j.esmoop.2021.100293.

Key clinical point: The risk for grade 3-4 (G3-4) neutropenia and febrile neutropenia (FN) is higher with FOLFOXIRI/bevacizumab vs doublets/bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC), with the risk being higher in older females, who may benefit with prophylactic use of granulocyte colony-stimulating factor.

Major finding: The incidence of G3-4 neutropenia (51% vs 21%; P < .001), FN (8% vs 4%; P = .02), and high-risk FN (3% vs 1%; P = .015) was significantly higher with FOLFOXIRI/bevacizumab vs doublet/bevacizumab, mostly during the first cycles. The risk for G3-4 neutropenia was significantly higher among older patients (P = .01) and females (P < .001).

Study details: This pooled analysis included 1,155 patients with untreated mCRC from TRIBE1 and TRIBE 2 phase 3 trials, of which 568 patients received FOLFOXIRI/bevacizumab and 587 received doublet/bevacizumab (FOLFIRI/bevacizumab; n=254 or FOLFOX/bevacizumab; n=335).

Disclosures: This study was supported by GONO and ARCO Foundations. Some of the authors declared receiving honoraria, travel grant, research funding, speakers’ bureau, and/or consulting or advisory role for various sources.

Source: Rossini D et al. ESMO Open. 2021 Oct 21. doi: 10.1016/j.esmoop.2021.100293.

Key clinical point: Women who underwent adenoma removal appear to be at a higher risk for colorectal cancer (CRC) incidence and CRC-related deaths, highlighting the need for sex-specific surveillance after adenoma removal.

Major finding: Compared with general population, CRC incidence was higher in women (standardized incidence ratios [SIR], 1.64; 95% CI, 1.54-1.74) than in men (SIR, 1.12; 95% CI, 1.05-1.19) who had adenomas removed. CRC mortality increased in women (standardized incidence-based mortality ratios [SMR], 1.13; 95% CI, 1.02-1.26) and reduced in men (SMR, 0.79; 95% CI, 0.71-0.89) who underwent adenoma removal compared with general population.

Study details: Findings are from a cohort study of 40,293 individuals who had their adenomas removed.

Disclosures: This work was supported by grants from Norwegian Research Council and Norwegian Cancer Society. The authors declared no conflict of interests.

Source: Jodal HC et al. Aliment Pharmacol Ther. 2021 Oct 30. doi: 10.1111/apt.16686.

Key clinical point: Women who underwent adenoma removal appear to be at a higher risk for colorectal cancer (CRC) incidence and CRC-related deaths, highlighting the need for sex-specific surveillance after adenoma removal.

Major finding: Compared with general population, CRC incidence was higher in women (standardized incidence ratios [SIR], 1.64; 95% CI, 1.54-1.74) than in men (SIR, 1.12; 95% CI, 1.05-1.19) who had adenomas removed. CRC mortality increased in women (standardized incidence-based mortality ratios [SMR], 1.13; 95% CI, 1.02-1.26) and reduced in men (SMR, 0.79; 95% CI, 0.71-0.89) who underwent adenoma removal compared with general population.

Study details: Findings are from a cohort study of 40,293 individuals who had their adenomas removed.

Disclosures: This work was supported by grants from Norwegian Research Council and Norwegian Cancer Society. The authors declared no conflict of interests.

Source: Jodal HC et al. Aliment Pharmacol Ther. 2021 Oct 30. doi: 10.1111/apt.16686.

Key clinical point: Women who underwent adenoma removal appear to be at a higher risk for colorectal cancer (CRC) incidence and CRC-related deaths, highlighting the need for sex-specific surveillance after adenoma removal.

Major finding: Compared with general population, CRC incidence was higher in women (standardized incidence ratios [SIR], 1.64; 95% CI, 1.54-1.74) than in men (SIR, 1.12; 95% CI, 1.05-1.19) who had adenomas removed. CRC mortality increased in women (standardized incidence-based mortality ratios [SMR], 1.13; 95% CI, 1.02-1.26) and reduced in men (SMR, 0.79; 95% CI, 0.71-0.89) who underwent adenoma removal compared with general population.

Study details: Findings are from a cohort study of 40,293 individuals who had their adenomas removed.

Disclosures: This work was supported by grants from Norwegian Research Council and Norwegian Cancer Society. The authors declared no conflict of interests.

Source: Jodal HC et al. Aliment Pharmacol Ther. 2021 Oct 30. doi: 10.1111/apt.16686.

Key clinical point: Pre-operative sarcopenia predicted shorter disease-free survival (DFS), overall survival (OS), and recurrence of the liver in patients with lower advanced rectal cancer receiving preoperative adjuvant chemoradiotherapy (CRT).

Major finding: Post-CRT sarcopenia was an independent prognostic factor for shorter DFS (hazard ratio [HR], 2.01; P = .049), OS (HR, 1.76; P = .036), and recurrence in the liver (HR, 3.01; P = .025).

Study details: Findings are from a retrospective analysis of 234 patients with cT3-T4 anyN M0 lower rectal cancer who underwent CRT (5-fluorouracil-based oral chemotherapy and long course radiation) followed by radical surgery.

Disclosures: This study was supported by Japan Society for the Promotion of Science and Japan Agency for Medical Research and Development. The authors declared no conflict of interests.

Source: Abe S et al. Int J Clin Oncol. 2021 Nov 6. doi: 10.1007/s10147-021-02062-z.

Key clinical point: Pre-operative sarcopenia predicted shorter disease-free survival (DFS), overall survival (OS), and recurrence of the liver in patients with lower advanced rectal cancer receiving preoperative adjuvant chemoradiotherapy (CRT).

Major finding: Post-CRT sarcopenia was an independent prognostic factor for shorter DFS (hazard ratio [HR], 2.01; P = .049), OS (HR, 1.76; P = .036), and recurrence in the liver (HR, 3.01; P = .025).

Study details: Findings are from a retrospective analysis of 234 patients with cT3-T4 anyN M0 lower rectal cancer who underwent CRT (5-fluorouracil-based oral chemotherapy and long course radiation) followed by radical surgery.

Disclosures: This study was supported by Japan Society for the Promotion of Science and Japan Agency for Medical Research and Development. The authors declared no conflict of interests.

Source: Abe S et al. Int J Clin Oncol. 2021 Nov 6. doi: 10.1007/s10147-021-02062-z.

Key clinical point: Pre-operative sarcopenia predicted shorter disease-free survival (DFS), overall survival (OS), and recurrence of the liver in patients with lower advanced rectal cancer receiving preoperative adjuvant chemoradiotherapy (CRT).

Major finding: Post-CRT sarcopenia was an independent prognostic factor for shorter DFS (hazard ratio [HR], 2.01; P = .049), OS (HR, 1.76; P = .036), and recurrence in the liver (HR, 3.01; P = .025).

Study details: Findings are from a retrospective analysis of 234 patients with cT3-T4 anyN M0 lower rectal cancer who underwent CRT (5-fluorouracil-based oral chemotherapy and long course radiation) followed by radical surgery.

Disclosures: This study was supported by Japan Society for the Promotion of Science and Japan Agency for Medical Research and Development. The authors declared no conflict of interests.

Source: Abe S et al. Int J Clin Oncol. 2021 Nov 6. doi: 10.1007/s10147-021-02062-z.

Key clinical point: The combination of immune checkpoint inhibitors (ICIs) with regorafenib showed promising efficacy in chemotherapy-refractory microsatellite stable (MSS) colorectal cancer (CRC).

Major finding: Overall, 5% and 45% of patients achieved partial response and stable disease as the best response, respectively. The median overall survival and progression-free survival (PFS) were 17.3 months (95% CI, 11.3-not reached) and 3.1 months (95% CI, 2.3-4.2), respectively, with 13% of patients achieving PFS of ≥6 months. Grade 3 or higher treatment-related adverse events were reported by 19% of patients.

Study details: Findings are from a retrospective analysis of 84 patients with chemotherapy-refractory advanced or metastatic MSS CRC who received at least 1 dose of ICIs combined with regorafenib.

Disclosures: This work was supported by grants from the National Natural Science Foundation of China and CAMS Innovation Fund for Medical Sciences. The authors declare no conflict of interests.

Source: Yang K et al. Cancer Immunol Immunother. 2021 Oct 24. doi: 10.1007/s00262-021-03083-3.

Key clinical point: The combination of immune checkpoint inhibitors (ICIs) with regorafenib showed promising efficacy in chemotherapy-refractory microsatellite stable (MSS) colorectal cancer (CRC).

Major finding: Overall, 5% and 45% of patients achieved partial response and stable disease as the best response, respectively. The median overall survival and progression-free survival (PFS) were 17.3 months (95% CI, 11.3-not reached) and 3.1 months (95% CI, 2.3-4.2), respectively, with 13% of patients achieving PFS of ≥6 months. Grade 3 or higher treatment-related adverse events were reported by 19% of patients.

Study details: Findings are from a retrospective analysis of 84 patients with chemotherapy-refractory advanced or metastatic MSS CRC who received at least 1 dose of ICIs combined with regorafenib.

Disclosures: This work was supported by grants from the National Natural Science Foundation of China and CAMS Innovation Fund for Medical Sciences. The authors declare no conflict of interests.

Source: Yang K et al. Cancer Immunol Immunother. 2021 Oct 24. doi: 10.1007/s00262-021-03083-3.

Key clinical point: The combination of immune checkpoint inhibitors (ICIs) with regorafenib showed promising efficacy in chemotherapy-refractory microsatellite stable (MSS) colorectal cancer (CRC).

Major finding: Overall, 5% and 45% of patients achieved partial response and stable disease as the best response, respectively. The median overall survival and progression-free survival (PFS) were 17.3 months (95% CI, 11.3-not reached) and 3.1 months (95% CI, 2.3-4.2), respectively, with 13% of patients achieving PFS of ≥6 months. Grade 3 or higher treatment-related adverse events were reported by 19% of patients.

Study details: Findings are from a retrospective analysis of 84 patients with chemotherapy-refractory advanced or metastatic MSS CRC who received at least 1 dose of ICIs combined with regorafenib.

Disclosures: This work was supported by grants from the National Natural Science Foundation of China and CAMS Innovation Fund for Medical Sciences. The authors declare no conflict of interests.

Source: Yang K et al. Cancer Immunol Immunother. 2021 Oct 24. doi: 10.1007/s00262-021-03083-3.

Key clinical point: Management of colorectal cancer (CRC) and synchronous liver metastases with staged liver-first or bowel-first routes or synchronous combined liver and bowel surgery, all with contemporary systemic chemotherapy, led to similar perioperative complications and oncological outcomes.

Major finding: Postoperative complications (P = .66), total critical care occupancy (P = .92) and mean total inpatient stay (P = .91) were similar between synchronous and staged management pathways. Overall, 35% of patients were disease-free at 12 months, with no difference between groups (P = .448).

Study details: Findings are from CoSMIC, a prospective inception cohort study including 125 patients with CRC and synchronous liver metastases.

Disclosures: AKC Chan was supported by a grant from the Dickinson Trust.

Source: Chan AKC et al. Ann Surg Oncol. 2021 Oct 30. doi: 10.1245/s10434-021-11017-7.

Key clinical point: Management of colorectal cancer (CRC) and synchronous liver metastases with staged liver-first or bowel-first routes or synchronous combined liver and bowel surgery, all with contemporary systemic chemotherapy, led to similar perioperative complications and oncological outcomes.

Major finding: Postoperative complications (P = .66), total critical care occupancy (P = .92) and mean total inpatient stay (P = .91) were similar between synchronous and staged management pathways. Overall, 35% of patients were disease-free at 12 months, with no difference between groups (P = .448).

Study details: Findings are from CoSMIC, a prospective inception cohort study including 125 patients with CRC and synchronous liver metastases.

Disclosures: AKC Chan was supported by a grant from the Dickinson Trust.

Source: Chan AKC et al. Ann Surg Oncol. 2021 Oct 30. doi: 10.1245/s10434-021-11017-7.

Key clinical point: Management of colorectal cancer (CRC) and synchronous liver metastases with staged liver-first or bowel-first routes or synchronous combined liver and bowel surgery, all with contemporary systemic chemotherapy, led to similar perioperative complications and oncological outcomes.

Major finding: Postoperative complications (P = .66), total critical care occupancy (P = .92) and mean total inpatient stay (P = .91) were similar between synchronous and staged management pathways. Overall, 35% of patients were disease-free at 12 months, with no difference between groups (P = .448).

Study details: Findings are from CoSMIC, a prospective inception cohort study including 125 patients with CRC and synchronous liver metastases.

Disclosures: AKC Chan was supported by a grant from the Dickinson Trust.

Source: Chan AKC et al. Ann Surg Oncol. 2021 Oct 30. doi: 10.1245/s10434-021-11017-7.

Key clinical point: Short-course radiotherapy (SCRT) combined with subsequent capecitabine plus oxaliplatin (CAPOX) and camrelizumab followed by delayed surgery showed remarkable pathological complete response (pCR) with manageable toxicity in patients with locally advanced rectal cancer (LARC).

Major finding: Overall, 48.1% of patients, including 46.2% patients with proficient mismatch repair tumors and 100% of patients with deficient mismatch repair tumors, achieved pCR. All immune-related adverse events were of grade 1-2, with the most common being reactive cutaneous capillary endothelial proliferation (81.5%).

Study details: Findings are from a single-arm, phase 2 trial including 30 patients with LARC, of which 27 received preoperative SCRT combined with subsequent CAPOX and camrelizumab followed by radical surgery after 1 week.

Disclosures: This work was supported by the Ministry of Science and Technology of China, 2018 National Natural Science Foundation of China, and Jiangsu Hengrui Pharmaceuticals Co., Ltd. T Zhang declared receiving research funding from and Z Hou and C Ma declared being employees of Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Source: Lin Z et al. J Immunother Cancer. 2021 Nov 1. doi: 10.1136/jitc-2021-003554.

Key clinical point: Short-course radiotherapy (SCRT) combined with subsequent capecitabine plus oxaliplatin (CAPOX) and camrelizumab followed by delayed surgery showed remarkable pathological complete response (pCR) with manageable toxicity in patients with locally advanced rectal cancer (LARC).

Major finding: Overall, 48.1% of patients, including 46.2% patients with proficient mismatch repair tumors and 100% of patients with deficient mismatch repair tumors, achieved pCR. All immune-related adverse events were of grade 1-2, with the most common being reactive cutaneous capillary endothelial proliferation (81.5%).

Study details: Findings are from a single-arm, phase 2 trial including 30 patients with LARC, of which 27 received preoperative SCRT combined with subsequent CAPOX and camrelizumab followed by radical surgery after 1 week.

Disclosures: This work was supported by the Ministry of Science and Technology of China, 2018 National Natural Science Foundation of China, and Jiangsu Hengrui Pharmaceuticals Co., Ltd. T Zhang declared receiving research funding from and Z Hou and C Ma declared being employees of Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Source: Lin Z et al. J Immunother Cancer. 2021 Nov 1. doi: 10.1136/jitc-2021-003554.

Key clinical point: Short-course radiotherapy (SCRT) combined with subsequent capecitabine plus oxaliplatin (CAPOX) and camrelizumab followed by delayed surgery showed remarkable pathological complete response (pCR) with manageable toxicity in patients with locally advanced rectal cancer (LARC).

Major finding: Overall, 48.1% of patients, including 46.2% patients with proficient mismatch repair tumors and 100% of patients with deficient mismatch repair tumors, achieved pCR. All immune-related adverse events were of grade 1-2, with the most common being reactive cutaneous capillary endothelial proliferation (81.5%).

Study details: Findings are from a single-arm, phase 2 trial including 30 patients with LARC, of which 27 received preoperative SCRT combined with subsequent CAPOX and camrelizumab followed by radical surgery after 1 week.

Disclosures: This work was supported by the Ministry of Science and Technology of China, 2018 National Natural Science Foundation of China, and Jiangsu Hengrui Pharmaceuticals Co., Ltd. T Zhang declared receiving research funding from and Z Hou and C Ma declared being employees of Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Source: Lin Z et al. J Immunother Cancer. 2021 Nov 1. doi: 10.1136/jitc-2021-003554.

Key clinical point: Higher consumption of preserved vegetables was associated with an increased prevalence of colorectal polyps as a precursor lesion of colorectal cancer (CRC), particularly small polyps in a population at high risk for CRC.

Major finding: Consumption of preserved vegetables was associated with an 18% higher prevalence of colorectal polyps (adjusted odds ratio highest vs lowest quartile [aOR_{Q4 vs Q1}], 1.18; P trend = .02) and 17% higher prevalence of small polyps (aOR_{Q4 vs Q1}, 1.17; P trend = .03).

Study details: Findings are from a survey analysis of 6,783 respondents from Lanxi Pre-colorectal Cancer Cohort who were at high risk for CRC.

Disclosures: This study was supported by Lanxi Municipal Government funds. The authors declared no conflict of interests.

Source: Wu F et al. Eur J Nutr. 2021 Nov 8. doi: 10.1007/s00394-021-02719-5.

Key clinical point: Higher consumption of preserved vegetables was associated with an increased prevalence of colorectal polyps as a precursor lesion of colorectal cancer (CRC), particularly small polyps in a population at high risk for CRC.

Major finding: Consumption of preserved vegetables was associated with an 18% higher prevalence of colorectal polyps (adjusted odds ratio highest vs lowest quartile [aOR_{Q4 vs Q1}], 1.18; P trend = .02) and 17% higher prevalence of small polyps (aOR_{Q4 vs Q1}, 1.17; P trend = .03).

Study details: Findings are from a survey analysis of 6,783 respondents from Lanxi Pre-colorectal Cancer Cohort who were at high risk for CRC.

Disclosures: This study was supported by Lanxi Municipal Government funds. The authors declared no conflict of interests.

Source: Wu F et al. Eur J Nutr. 2021 Nov 8. doi: 10.1007/s00394-021-02719-5.

Key clinical point: Higher consumption of preserved vegetables was associated with an increased prevalence of colorectal polyps as a precursor lesion of colorectal cancer (CRC), particularly small polyps in a population at high risk for CRC.

Major finding: Consumption of preserved vegetables was associated with an 18% higher prevalence of colorectal polyps (adjusted odds ratio highest vs lowest quartile [aOR_{Q4 vs Q1}], 1.18; P trend = .02) and 17% higher prevalence of small polyps (aOR_{Q4 vs Q1}, 1.17; P trend = .03).

Study details: Findings are from a survey analysis of 6,783 respondents from Lanxi Pre-colorectal Cancer Cohort who were at high risk for CRC.

Disclosures: This study was supported by Lanxi Municipal Government funds. The authors declared no conflict of interests.

Source: Wu F et al. Eur J Nutr. 2021 Nov 8. doi: 10.1007/s00394-021-02719-5.